Amgen (NASDAQ:AMGN) Earns “Neutral” Rating from Cantor Fitzgerald

Amgen (NASDAQ:AMGN)‘s stock had its “neutral” rating reiterated by analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $400.00 target price on the medical research company’s stock. Cantor Fitzgerald’s target price indicates a potential downside of 8.51% from the stock’s previous close.

Several other analysts have also commented on AMGN. Mizuho increased their price target on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Daiwa Securities Group decreased their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Wells Fargo & Company lifted their price target on shares of Amgen from $400.00 to $435.00 and gave the stock an “equal weight” rating in a report on Friday. Argus increased their price objective on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Finally, Canaccord Genuity Group boosted their target price on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $381.68.

Amgen Price Performance

Amgen stock opened at $437.23 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $236.38 billion, a P/E ratio of 27.17, a P/E/G ratio of 3.15 and a beta of 0.43. The business has a fifty day moving average of $398.92 and a two-hundred day moving average of $367.59. Amgen has a twelve month low of $269.77 and a twelve month high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts forecast that Amgen will post 22.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its stake in shares of Amgen by 36,047.1% in the 2nd quarter. California State Teachers Retirement System now owns 298,255,793 shares of the medical research company’s stock valued at $108,004,388,000 after buying an additional 297,430,677 shares during the period. Norges Bank purchased a new position in Amgen in the fourth quarter worth approximately $2,164,162,000. Bank of America Corp DE acquired a new stake in Amgen during the second quarter worth $1,831,903,000. Capital World Investors raised its position in Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Finally, Wellington Management Group LLP grew its holdings in shares of Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after purchasing an additional 2,514,254 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s olpasiran remains a potentially significant opportunity in the Lp(a)-lowering market. The Novartis result does not determine olpasiran’s outcome, leaving room for Amgen to differentiate its drug if its late-stage trial demonstrates a reduction in cardiovascular events. Cholesterol drug setback casts doubt over multibillion-dollar race
• Neutral Sentiment: The disappointing Novartis data is affecting several companies pursuing Lp(a) therapies, including Amgen and Eli Lilly, reflecting broader investor caution toward experimental drug pipelines rather than a change to Amgen’s current operating results. Why Amgen Stock Is Dropping After Swiss Rival’s Trial Setback
• Negative Sentiment: Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering harmful Lp(a) cholesterol. Investors now face greater uncertainty over whether Amgen’s olpasiran can validate the same biological mechanism in its approximately 7,297-patient heart-outcomes study. Amgen’s 7,297-Patient Heart Bet Just Inherited a Higher Bar
• Negative Sentiment: The trial failure has already prompted investor concern about olpasiran’s phase 3 prospects, making the drug a higher-risk pipeline asset and contributing to the recent pullback in AMGN. Amgen Shares Fall as Novartis’ Pelacarsen Misses Phase III Study Goal

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.